

Victory Square Technologies Portfolio Company Establishes Distribution Network in Hong Kong, Philippines, Malaysia, Thailand, & Singapore for Safetest Covid-19 Testing Kits

- Victory Square Health's newly announced distribution network will provide accurate and affordable Safetest Covid-19 testing kits in Hong Kong, Philippines, Malaysia, Thailand, & Singapore
- Sales and distribution of VS Health products subject to Government/Health approvals.
- Safetest Covid-19 Testing kits can confirm whether one is currently infected with the virus causing Covid-19 or whether one was infected before and was unaware of the infection

VANCOUVER, British Columbia, OCT. 15, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. ("VS Health" or the "Company") – a portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) -- is pleased to announce that it has established a distribution network in Hong Kong, Philippines, Malaysia, Thailand and Singapore to make available its Safetest Covid-19 Testing Kits across the region.

The new partnerships with Hong Kong-based Nupaf Ltd., Jaya Unggul Gemilang Sdn Bhd in Malaysia, an associate company of the Singapore-based Olim Het Pte. Ltd. and Added Value Business and Marketing Solutions Inc. based in the Philippines, will provide the region with access to VS Health's ELISA and Safetest 15 Minute Rapid Covid-19 assay for detecting the antibodies IgG and IgM against SARS-CoV-2. This will commence immediately following regional approvals.

Over the past decade, NUPAF's diverse client base includes organizations such as the United Nations and NATO to hotel chains including Sheraton, Ritz Carlton and exclusive private clubs. "We are very pleased and proud to work with Victory Square," said Francis Anthony of Jaya Unggul Gemilang Sdn Bhd in Malaysia, an associate company of the Singapore-based Olim Het Pte. Ltd., which specialises in the sourcing of medical products/supplies with clients in Singapore, Malaysia, Thailand and Australia.

The Safetest 15 Minute Covid-19 Rapid Test enables the user to receive results with a 96.6% sensitivity in 15 minutes by a simple blood sample similar to that of a hand held diabetes reader that resembles a pregnancy test stick. This highly accurate test enables the participant to quickly detect if they have Covid-19 antibodies in 15 minutes.

The Safetest 15 Minute Covid-19 Rapid Test has been granted permission by the Food & Drug Administration (FDA) in the United States to commence marketing, sales and distribution under the emergency use authorization (EUA). The Safetest 15 Minute Covid-19 Rapid Test has been submitted for review and approval in Canada and the European Union.

The newly created VS Health network in South East Asia will also receive access to the company's other antibody-based tests and its robust R&D pipeline of diagnostic kits for Hansen's Disease, Brucellosis, HTLV and Blood samples screening tests.

Many countries in South East Asia are in the grips of a second pandemic shutdown, and the deployment of rapid tests is seen as the best way to support sectors of the economy that have been crushed by public health measures meant to slow the spread of Covid-19.

"Rapid tests to detect the presence of the virus, which are faster and cheaper, are a vital addition to the testing arsenal needed to contain and fight Covid-19 in the region," said Victory Square CEO Shafin Diamond Tejani. "Our company is now collaborating with our distributors in Asia in submitting for health and government approvals," he said.

VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient's care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen's Disease, Brucellosis, HTLV and Blood samples screening tests.

Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Go to: VictorySquare.com and sign up for VST's official newsletter at www.VictorySquare.com/newsletter

On behalf of the board,

Shafin Diamond Tejani

Chief Executive Officer

Victory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact – Alex Tzilios

Email: alexandros@victorysquare.com

Telephone: 778-867-0482

Media Relations Contact – Howard Blank, Director

Email: howard@victorysquare.com

Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.

VST's sweet spot is the cutting-edge tech that's shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isn't just another investor. With real skin in the game, we're committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you'll scale and be ready to monetize.

What we do differently for investors

VST is a publicly traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they're unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

Forward Looking Statement

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements

of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.